Leadership at bioLytical®

Executive Team

Livleen Veslemes

Chief Operating Officer
Chief Financial Officer
More

Livleen Veslemes has over 15 years of financial management experience in private and public companies across several different industries including biotechnology. Livleen served as Chief Financial Officer of a Vancouver based publicly traded medical diagnostic manufacturer with FDA cleared products that transitioned from the R&D phase into full commercialization through worldwide partnerships with 3M Healthcare, Roche Diagnostics and other international distributors. She also served as the Director of Finance at a subsidiary of Bell Canada and a leading North American provider of satellite communication solutions. She successfully led the financial integration of three North American acquisitions, managed the accounting and finance functions through a period of exponential revenue growth, and was responsible for consolidated financial statements for 2 US subsidiaries and 5 Canadian offices during her tenure there. Immediately prior to joining bioLytical Laboratories in October 2014, Livleen was an executive team member at Luvo Inc. reporting directly to the CEO, hired at startup to develop and lead accounting, finance, supply chain, legal, HR, administration and information systems. She facilitated the implementation of a strategic plan that resulted in the launch of 34 USDA approved products with 5,500 retailers in the US including Whole Foods, Safeway, Target and Costco. Livleen earned her designation as a Certified Management Accountant (CMA) in 2001.

Executive Team

Stan Miele

Chief Commercial Officer
More

Stan Miele joined bioLytical Laboratories in March of 2016 as the Chief Commercial Officer. He is an accomplished global executive with over 25 years of sales and marketing experience. He has had success in sales, marketing and P&L leadership in the pharmaceuticals, medical device, diagnostics and biotech industries. He has a proven record of accelerating sales and enhancing profitability, building commercial organizations, negotiating global alliances and leading product launches. His previous role was with Sucampo Pharmaceuticals Inc. where he served as Chief Commercial Officer. He was also the former President of Sucampo Pharma Americas, LLC, since 2009 where he played an important role in in the company achieving profitability in 2013. Mr. Miele joined Sucampo in 2006 as National Director of Sales and was subsequently promoted to Senior Vice President of Sales and Marketing in 2008.

Prior to joining Sucampo, Mr. Miele was the i-STAT Executive Sales Manager for Abbott Diagnostics, a division of global healthcare company Abbott Laboratories, from 2005 to 2006. From 1998 to 2005, he held a series of positions at Millennium Pharmaceuticals and at COR Therapeutics, including National Sales Director, Cardiology. He was also instrumental in the development and launch of an office based cardiovascular sales team during his tenure at Millennium.

Mr. Miele began his career as a sales representative both at the Hospital Products Division of Abbott Laboratories, and at Syntex Labs. He also has served in the military as an officer in the US Army and Army National Guard.

Mr. Miele earned a bachelor’s degree in management communications from the University of Dayton.

Executive Team

Rick Galli

Chief Technical Officer
More

After graduation from the University of Windsor with a degree in Microbiology, Rick Galli began his extensive career in research and diagnostic laboratory sciences with the Ontario Ministry of Health and Long Term Care Public Health Laboratory in 1973. Since then he has worked in senior positions in public and hospital laboratory settings as well as the private sector. He was directly involved with leadership of laboratory diagnosis and monitoring of HIV infection from 1987 to 2005, and served on numerous HIV advisory boards and associations, most recently as President of the Canadian Association of HIV Clinical Laboratory Specialists. Before moving to Vancouver and joining the BC Centre for Excellence in HIV/AIDS in 1999, Rick initiated the first and only provincial peer-reviewed HIV/AIDS grants and awards program of its kind for Ontario-based researchers, through the Ontario HIV Treatment Network in Toronto. From 1999 to 2005, Rick helped establish and managed the first accredited HIV molecular laboratory monitoring program in Canada at the BC Center for Excellence in HIV/AIDS. Since joining bioLytical Laboratories in February 2005, Rick has been instrumental in directing the regulatory compliance elements for bioLytical and INSTI that resulted in Health Canada approval, CE Marking for European Union member countries, WHO prequalification and US FDA approval and CLIA waiver. Mr. Galli is responsible for bioLytical Laboratories' regulatory, scientific and clinical affairs.

You are currently viewing content for the US region. Accept